Assessment Of The Pulmonary Arterial Hypertension (PAH) Market 2026-2036 Featuring United Therapeutics, Mochida Pharmaceutical, Johnson & Johnson, Merck, And Gossamer Bio
The pulmonary arterial hypertension (PAH) market across the United States, EU4 countries-Germany, France, Italy, and Spain-the United Kingdom, and Japan reached approximately USD 8 billion in 2025. The market is projected to expand at a compound annual growth rate of 6.7% from 2022 to 2036, supported by rising diagnosis rates, greater use of combination therapy, and the anticipated introduction of novel treatments.
The report provides a comprehensive assessment of PAH epidemiology, treatment practices, market dynamics, drug uptake, pricing, reimbursement, and competitive developments across the seven major markets. It includes historical and forecast analyses for 2022-2036, supported by epidemiology-based forecasting, expert interviews, and qualitative market intelligence.
PAH Epidemiology and Patient Burden
PAH remains a rare, progressive, and life-threatening condition associated with substantial morbidity, impaired quality of life, right heart failure, and premature mortality. Epidemiological assessment continues to be constrained by regional data variability, inconsistent diagnostic methodologies, nonspecific clinical presentation, and underdiagnosis.
The United States recorded approximately 50,000 prevalent PAH cases and an estimated 40,000-44,000 diagnosed prevalent cases in 2025. Idiopathic and heritable PAH represented the largest subtype, accounting for nearly 19,000 US cases. Germany reported the highest diagnosed prevalence among the EU4 and the United Kingdom, with approximately 7,000 cases. In Japan, diagnosed prevalence included nearly 19,000 female patients and 5,000 male patients. Diagnosed patient populations are expected to increase through 2036.
Current PAH Treatment Landscape
PAH treatment aims to improve symptoms, exercise capacity, quality of life, and survival while reducing clinical worsening. Therapeutic decisions are increasingly guided by risk stratification using clinical, functional, and hemodynamic parameters.
Current pharmacological management targets the prostacyclin, endothelin, and nitric oxide pathways. Major treatment classes include phosphodiesterase type 5 inhibitors, soluble guanylate cyclase stimulators, endothelin receptor antagonists, and prostacyclin analogs and receptor agonists. Established products include UPTRAVI, TYVASO, ADEMPAS, ORENITRAM, OPSYNVI/YUVANCI, and WINREVAIR.
Macitentan remains an important endothelin receptor antagonist, while prostacyclin pathway therapies include epoprostenol, iloprost, treprostinil, and selexipag. Treatment delivery has evolved across intravenous, subcutaneous, inhaled, and oral formulations, improving therapeutic flexibility and supporting individualized care.
In May 2025, the US Food and Drug Administration approved Liquidia's YUTREPIA, a treprostinil inhalation powder, for adults with PAH and pulmonary hypertension associated with interstitial lung disease. The product uses PRINT technology and a portable dry powder inhaler to support pulmonary delivery.
PAH Pipeline and Emerging Therapies
The PAH pipeline includes candidates designed to improve efficacy, convenience, durability, and disease modification. Notable emerging therapies include ralinepag from United Therapeutics, seralutinib from Gossamer Bio, RT234 from Respira Therapeutics, and L606 from Pharmosa Biopharm and Liquidia.
Ralinepag is an oral, selective prostacyclin receptor agonist under development for PAH. In March 2026, United Therapeutics reported a 55% reduction in the risk of clinical worsening in a pivotal study. The company intends to submit a New Drug Application to the FDA in the second half of 2026.
Gossamer Bio announced topline Phase III results for inhaled seralutinib in February 2026. Seralutinib targets signaling associated with pulmonary vascular remodeling. RT234 is an inhaled, as-needed vardenafil therapy intended to address exertional symptoms alongside chronic background treatment. L606 is a liposomal treprostinil formulation being evaluated as another potential advancement in inhaled therapy.
PAH Market Outlook, Pricing, and Access
The combined PAH market in the EU4 and the United Kingdom was estimated at approximately USD 400 million in 2025. Germany accounted for the largest regional share at around USD 100 million, followed by France and the United Kingdom at approximately USD 80 million each. Japan's PAH market totaled about USD 300 million and is forecast to grow from 2026 through 2036.
Pricing, reimbursement, patient access, and cost-effectiveness will remain central to commercial performance. High treatment costs can affect formulary positioning, adherence, and long-term uptake. UPTRAVI, for example, has an estimated annual treatment cost of approximately USD 260,000 in the United States. The report evaluates country-level reimbursement environments, affordability programs, public prescription coverage, analogue-based pricing, and alternative payment approaches.
Key Unmet Needs and Competitive Opportunities
- More reliable and current epidemiological evidence Validated biomarkers and improved diagnostic pathways Earlier diagnosis and stronger disease awareness Disease-modifying and curative targeted therapies More comprehensive treatment algorithms Improved access, affordability, adherence, and route-of-administration options
Leading and emerging PAH companies include United Therapeutics, Johnson & Johnson, Merck, Gossamer Bio, Mochida Pharmaceutical, Liquidia, Pharmosa Biopharm, and Respira Therapeutics. Competitive analysis covers approved and investigational therapies, clinical evidence, regulatory milestones, patents, partnerships, market share, peak uptake, and anticipated sales.
Report Coverage and Strategic Value
The report assesses PAH patient population forecasts, therapeutic market size, treatment algorithms, pipeline activity, drug adoption, peak patient share, pricing trends, reimbursement, and market opportunities. SWOT and attribute analyses compare therapies based on efficacy, safety, tolerability, administration frequency, route of administration, development probability, market-entry timing, and addressable patient population.
Insights were validated through primary research with more than eight key opinion leaders and subject-matter experts across major institutions, including the University of Pennsylvania Hospital, the University of Chicago, the University of Pittsburgh, and Hannover Medical School. These perspectives address prescribing behavior, treatment switching, adherence, access barriers, diagnosis patterns, and emerging therapy adoption.
The PAH market report supports pharmaceutical companies, investors, healthcare organizations, and other stakeholders seeking to understand disease burden, competitive positioning, treatment innovation, and commercial opportunities through 2036. Its epidemiology-based forecasting and AI-enabled analysis convert complex market datasets into actionable intelligence for clinical development, portfolio planning, pricing, market access, and launch strategy.
A selection of companies mentioned in this report includes, but is not limited to:
- United Therapeutics Mochida Pharmaceutical Johnson & Johnson Merck Gossamer Bio
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment